A proof of concept case series of botulinum toxin a treatment for ischemic feet due to Raynaud’s phenomenon
Journal of Plastic, Reconstructive & Aesthetic Surgery · 2026-06 · 117 · 222-225
DOI: 10.1016/j.bjps.2026.04.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Plastic, Reconstructive & Aesthetic Surgery, 2026-06. Verfasst von L F Stadelmeier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address: adowla…. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Raynaud Disease, Ischemia, Foot. Die Arbeit nennt 4 Literaturangaben.
Abstract (Originalsprache)
Botulinum Toxin A (BTX-A) has shown benefit in treating Raynaud's phenomenon (RP) of the hands, but its use in the feet remains largely unreported. We present a retrospective case series of seven patients undergoing 11 BTX-A treatment sessions for refractory ischemic RP of the feet. Injections (100-150 units per foot) were administered under ultrasound guidance. At six weeks, 81.8% of treatment episodes demonstrated resolution of ulcers and/or gangrene. Pain significantly improved (p=0.013), with the proportion of pain-free cases increasing from 9.1% to 63.6%. One transient adverse event was observed. These findings suggest that BTX-A may represent a safe and promising treatment option for ischemic RP of the feet, warranting further investigation in prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address: adowlats@bidmc.harvard.edu.
- Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
- Department of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
- Department of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
Zitieren
APA
Stadelmeier, L. F., Eeuwen, J. E., Engmann, T. F., Hilbig-Vlatten, L., Carroll, B. J., Nashel, J., & Dowlatshahi, A. S. (2026). A proof of concept case series of botulinum toxin a treatment for ischemic feet due to Raynaud’s phenomenon. Journal of Plastic, Reconstructive & Aesthetic Surgery, 117, 222-225. https://doi.org/10.1016/j.bjps.2026.04.028
Vancouver
Stadelmeier LF, Eeuwen JE, Engmann TF, Hilbig-Vlatten L, Carroll BJ, Nashel J, et al. A proof of concept case series of botulinum toxin a treatment for ischemic feet due to Raynaud’s phenomenon. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2026;117:222-225. doi:10.1016/j.bjps.2026.04.028
BibTeX
@article{Stadelmeier2026,
author = {Stadelmeier, L F and Eeuwen, J E and Engmann, T F and Hilbig-Vlatten, L and Carroll, B J and Nashel, J and Dowlatshahi, A S},
title = {A proof of concept case series of botulinum toxin a treatment for ischemic feet due to Raynaud’s phenomenon},
journal = {Journal of Plastic, Reconstructive & Aesthetic Surgery},
year = {2026},
volume = {117},
pages = {222--225},
doi = {10.1016/j.bjps.2026.04.028}
}
EUVIMED